Literature DB >> 22247460

Relationships among multifocal electroretinogram amplitude, visual field sensitivity, and SD-OCT receptor layer thicknesses in patients with retinitis pigmentosa.

Yuquan Wen1, Martin Klein, Donald C Hood, David G Birch.   

Abstract

PURPOSE: To compare local functional measures, the multifocal electroretinogram (mfERG) and visual field sensitivity, with a local structural measure, spectral domain (SD) optical coherence tomography (OCT), of receptor damage in patients with retinitis pigmentosa (RP).
METHODS: MfERGs, visual fields, and SD-OCT scans were obtained from 10 patients with RP, ranging in age from 23 to 59 years. Average amplitudes, average linear sensitivities, and average layer thicknesses were measured from within the central 3° and from three concentric annuli located between 3° and 8°, 8° and 15°, and 15° and 24°. A computer program aided manual segmentation and calculated OCT thickness in the scans.
RESULTS: Within each patient with RP, mfERG amplitude for each circle/annulus was highly correlated with corresponding layer thicknesses in the outer retina (r = 0.88 to 0.99), but not at all correlated with thickness of the inner nuclear layer or total retina. Across all ring eccentricities, relative mfERG amplitude and relative visual field sensitivity were correlated with relative SD-OCT outer retinal thickness.
CONCLUSIONS: In patients with RP, preserved cone photoreceptor function measured by mfERG amplitude and visual field sensitivity correlate well with the remaining thickness of the photoreceptor layer. All three measures show comparable relative loss beyond 3° eccentricity. In the fovea, SD-OCT outer retina thickness showed less relative loss than either mfERG or visual field sensitivity.

Entities:  

Mesh:

Year:  2012        PMID: 22247460      PMCID: PMC3317422          DOI: 10.1167/iovs.11-8410

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  30 in total

1.  The transition zone between healthy and diseased retina in patients with retinitis pigmentosa.

Authors:  Donald C Hood; Margot A Lazow; Kirsten G Locke; Vivienne C Greenstein; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-05       Impact factor: 4.799

2.  ISCEV Standard for full-field clinical electroretinography (2008 update).

Authors:  M F Marmor; A B Fulton; G E Holder; Y Miyake; M Brigell; M Bach
Journal:  Doc Ophthalmol       Date:  2008-11-22       Impact factor: 2.379

3.  Correlation between macular volume and focal macular electroretinogram in patients with retinitis pigmentosa.

Authors:  Tadasu Sugita; Mineo Kondo; Chang-Hua Piao; Yasuki Ito; Hiroko Terasaki
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-25       Impact factor: 4.799

4.  Human chorioretinal layer thicknesses measured in macula-wide, high-resolution histologic sections.

Authors:  Christine A Curcio; Jeffrey D Messinger; Kenneth R Sloan; Arnab Mitra; Gerald McGwin; Richard F Spaide
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-06       Impact factor: 4.799

5.  A comparison of visual field sensitivity to photoreceptor thickness in retinitis pigmentosa.

Authors:  Nalini V Rangaswamy; Hemaxi M Patel; Kirsten G Locke; Donald C Hood; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-10       Impact factor: 4.799

6.  Rate of visual field loss in retinitis pigmentosa.

Authors:  S Grover; G A Fishman; R J Anderson; K R Alexander; D J Derlacki
Journal:  Ophthalmology       Date:  1997-03       Impact factor: 12.079

7.  Macular atrophy in birdshot retinochoroidopathy: an optical coherence tomography and multifocal electroretinography analysis.

Authors:  David G Birch; Patrick D Williams; David Callanan; Robert Wang; Kirsten G Locke; Donald C Hood
Journal:  Retina       Date:  2010-06       Impact factor: 4.256

8.  Thickness of receptor and post-receptor retinal layers in patients with retinitis pigmentosa measured with frequency-domain optical coherence tomography.

Authors:  Donald C Hood; Christine E Lin; Margot A Lazow; Kirsten G Locke; Xian Zhang; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-14       Impact factor: 4.799

9.  A comparison of multifocal ERG and frequency domain OCT changes in patients with abnormalities of the retina.

Authors:  Elizabeth A Dale; Donald C Hood; Vivienne C Greenstein; Jeffrey G Odel
Journal:  Doc Ophthalmol       Date:  2009-12-31       Impact factor: 2.379

10.  Normal central retinal function and structure preserved in retinitis pigmentosa.

Authors:  Samuel G Jacobson; Alejandro J Roman; Tomas S Aleman; Alexander Sumaroka; Waldo Herrera; Elizabeth A M Windsor; Lori A Atkinson; Sharon B Schwartz; Janet D Steinberg; Artur V Cideciyan
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-09-24       Impact factor: 4.799

View more
  35 in total

1.  Photoreceptor dysfunction in early and intermediate age-related macular degeneration assessed with mfERG and spectral domain OCT.

Authors:  Shasha Yang; Chengguo Zuo; Hui Xiao; Lan Mi; Guangwei Luo; Xiaoyu Xu; Xing Liu
Journal:  Doc Ophthalmol       Date:  2016-01-11       Impact factor: 2.379

2.  Time and frequency components of ERG responses in retinitis pigmentosa.

Authors:  Samira Ebdali; Bijan Hashemi; Hassan Hashemi; Ebrahim Jafarzadehpur; Soheila Asgari
Journal:  Int Ophthalmol       Date:  2017-11-30       Impact factor: 2.031

3.  Association between multifocal electroretinograms, optical coherence tomography and central visual sensitivity in advanced retinitis pigmentosa.

Authors:  Chan Hee Moon; Tae Kwann Park; Young-Hoon Ohn
Journal:  Doc Ophthalmol       Date:  2012-08-03       Impact factor: 2.379

4.  Preserved functional and structural integrity of the papillomacular area correlates with better visual acuity in retinitis pigmentosa.

Authors:  K Konieczka; R I Bojinova; C Valmaggia; D F Schorderet; M G Todorova
Journal:  Eye (Lond)       Date:  2016-08-05       Impact factor: 3.775

5.  Allele-Specific Inhibition of Rhodopsin With an Antisense Oligonucleotide Slows Photoreceptor Cell Degeneration.

Authors:  Susan F Murray; Ali Jazayeri; Michael T Matthes; Douglas Yasumura; Haidong Yang; Raechel Peralta; Andy Watt; Sue Freier; Gene Hung; Peter S Adamson; Shuling Guo; Brett P Monia; Matthew M LaVail; Michael L McCaleb
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

6.  Higher retinal vessel oxygen saturation: investigating its relationship with macular oedema in retinitis pigmentosa patients.

Authors:  Rossiana I Bojinova; Daniel F Schorderet; Christophe Valmaggia; Cengiz Türksever; Andreas Schoetzau; Margarita G Todorova
Journal:  Eye (Lond)       Date:  2018-03-06       Impact factor: 3.775

7.  Rates of decline in regions of the visual field defined by frequency-domain optical coherence tomography in patients with RPGR-mediated X-linked retinitis pigmentosa.

Authors:  David G Birch; Kirsten G Locke; Joost Felius; Martin Klein; Dianna K H Wheaton; Dennis R Hoffman; Donald C Hood
Journal:  Ophthalmology       Date:  2014-12-31       Impact factor: 12.079

8.  Neogenin neutralization prevents photoreceptor loss in inherited retinal degeneration.

Authors:  Jason Charish; Alireza P Shabanzadeh; Danian Chen; Patrick Mehlen; Santhosh Sethuramanujam; Hidekiyo Harada; Vera L Bonilha; Gautam Awatramani; Rod Bremner; Philippe P Monnier
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

9.  Normative reference ranges for the retinal nerve fiber layer, macula, and retinal layer thicknesses in children.

Authors:  Susan E Yanni; Jingyun Wang; Christina S Cheng; Kelly I Locke; Yuquan Wen; David G Birch; Eileen E Birch
Journal:  Am J Ophthalmol       Date:  2012-11-03       Impact factor: 5.258

10.  Quantification of Ellipsoid Zone Changes in Retinitis Pigmentosa Using en Face Spectral Domain-Optical Coherence Tomography.

Authors:  Amir H Hariri; Hong Yang Zhang; Alexander Ho; Peter Francis; Richard G Weleber; David G Birch; Frederick L Ferris; SriniVas R Sadda
Journal:  JAMA Ophthalmol       Date:  2016-06-01       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.